

Opioids in Chronic Non-Cancer Pain: The Basics


Reference List

1. Chou R, Ballantyne JC, Fanciullo GJ, Fine PG, Miaskowski C. Research gaps on use of opioids for chronic noncancer pain: findings from a review of the evidence for an American Pain Society and American Academy of Pain Medicine clinical practice guideline. *J Pain* 2009 Feb;10(2):147-159.
2. Furlan A, Chaparro LE, Irvin E, Mailis-Gagnon A. A comparison between enriched and nonenriched enrollment randomized withdrawal trials of opioids for chronic noncancer pain. *Pain Res Manag* 2011 Sep-Oct;16(5):337-351.
3. Juurlink DN, Dhalla IA. Dependence and addiction during chronic opioid therapy. *J Med Toxicol* 2012 Dec;8(4):393-399.
4. Ballantyne JC. "Safe and effective when used as directed": the case of chronic use of opioid analgesics. *J Med Toxicol* 2012 Dec;8(4):417-423.
5. Moore RA, Eccleston C, Derry S, Wiffen P, Bell RF, Straube S, et al. "Evidence" in chronic pain -- establishing best practice in the reporting of systematic reviews. *Pain* 2010 09/01;150(3):386-389.
6. Nuesch E, Rutjes AW, Husni E, Welch V, Juni P. Oral or transdermal opioids for osteoarthritis of the knee or hip. *Cochrane Database Syst Rev* 2009 Oct 7;4(CD003115):50.
7. National Prescribing Service (NPS). Opioids in chronic non-cancer pain: use a planned approach. 2010; Available at: http://www.nps.org.au/_data/assets/pdf_file/0012/89886/PPR51_opioids_noncancer_pain_0710.pdf. Accessed June 17, 2013.
8. Chou R, Fanciullo GJ, Fine PG, Adler JA, Ballantyne JC, Davies P, et al. Clinical guidelines for the use of chronic opioid therapy in chronic noncancer pain. *J Pain* 2009 Feb;10(2):113-130.
9. National Opioid Use Guideline Group (NOUGG). Canadian Guideline for Safe and Effective Use of Opioids for Chronic Non-Cancer Pain. 2010; Available at: <http://nationalpaincentre.mcmaster.ca/opioid/>. Accessed June 17, 2013.
10. Department of Veterans Affairs, Department of Defense. VA/DOD clinical practice guideline for management of opioid therapy for chronic pain. 2010; Available at: http://www.healthquality.va.gov/Chronic_Opioid_Therapy_COT.asp. Accessed June 17, 2013.
11. University of Wisconsin Hospital & Clinics. Pain Care Services. Pain care fast facts: 5-minute clinical inservice: establishing pain relief goals. 2nd edition, 5/010. Available at: <http://prc.coh.org/pdf/Goals-FF%205-10.pdf>. Accessed June 17, 2013.

12. Bovend'Eerd TJ, Botell RE, Wade DT. Writing SMART rehabilitation goals and achieving goal attainment scaling: a practical guide. *Clin Rehabil* 2009 Apr;23(4):352-361.
13. Furlan A. Practical aspects of prescribing opioids for patients with chronic pain. 2012; Available at: <http://www.rheumatology.utoronto.ca/Assets/Rheumatology+Digital+Assets/Dr.+A.+Furlan.pdf>. Accessed June 17, 2013.
14. National Prescribing Service (NPS). Opioid therapy in chronic pain: case study 64 report. 2010; Available at: http://www.nps.org.au/data/assets/pdf_file/0011/108110/Case-64-report.pdf. Accessed June 17, 2013.
15. Moore A, Derry S, Eccleston C, Kalso E. Expect analgesic failure; pursue analgesic success. *BMJ* 2013 May 3;346:f2690.
16. Group Health. Principles for more selective and cautious opioid prescribing. 2012; Available at: <http://www.ghinnovates.org/?p=3573>. Accessed June 17, 2013.
17. Norman J, Caisley C. How to tackle the prescription opioid crisis. *BMJ* 2011 Oct 4;343:d6341.
18. Canadian Agency for Drugs and Technologies in Health. CEDAC final recommendation: buprenorphine transdermal patch resubmission (BuTrans – Purdue Pharma). Indication: pain, persistent (moderate intensity). 2011; Available at: http://www.cadth.ca/media/cdr/complete/cdr_complete_Butrans-September-30-2011.pdf. Accessed June 17, 2013.
19. Canadian Agency for Drugs and Technologies in Health. CEDAC final recommendation and reasons for recommendation: tapentadol (Nucynta CR – Janssen Inc.). 2011; Available at: http://www.cadth.ca/media/cdr/complete/cdr_complete_Nucynta_September-30-2011.pdf. Accessed June 17, 2013.
20. Canadian Agency for Drugs and Technologies in Health. CEDAC final recommendation on reconsideration and reasons for recommendation: tramadol hydrochloride (Zytram XL® - Purdu Pharma). 2007; Available at: http://www.cadth.ca/media/cdr/complete/cdr_complete_ZytramXL_September-26-2007.pdf. Accessed June 17, 2013.
21. Canadian Agency for Drugs and Technologies in Health. CEDAC final recommendation and reasons for recommendation: tramadol hydrochloride (Tridural™ – Paladin Labs Inc.). 2008; Available at: http://www.cadth.ca/media/cdr/complete/cdr_complete_Tridural_April-17-2008.pdf. Accessed June 17, 2013.
22. Canadian Agency for Drugs and Technologies in Health. CEDAC final recommendation on reconsideration and reasons for recommendation: tramadol hydrochloride (Ralivia™ - Biovail Pharmaceuticals Canada). 2008; Available at: http://www.cadth.ca/media/cdr/complete/cdr_complete_Ralivia_June_25_2008.pdf. Accessed June 17, 2013.
23. Canadian Agency for Drugs and Technologies in Health. CEDAC final recommendation and reasons for recommendation: tramadol hydrochloride/acetaminophen (Tramacet™ – Janssen-Ortho Inc.). 2008; Available at: http://www.cadth.ca/media/cdr/complete/cdr_complete_Tramacet_May17-07.pdf. Accessed June 17, 2013.
24. Canadian Agency for Drugs and Technologies in Health. The use of OxyNeo® and OxyContin® in adults: a review of the evidence on safety. 2011; Available at: http://www.cadth.ca/media/pdf/htis/sept-2011/RC0301_OxyNEO_final.pdf. Accessed June 17, 2013.
25. Carson S, Thakurta S, Low A, Smith B, Chou R. Drug Effectiveness Review Project. Drug class review: long-acting opioid analgesics. Update 6 final report. 2011; Available at: http://derp.ohsu.edu/final/Opioids_final_report_update%206_Jul_11.pdf. Accessed June 17, 2013.
26. Argoff CE, Silvershein DI. A comparison of long- and short-acting opioids for the treatment of chronic noncancer pain: tailoring therapy to meet patient needs. *Mayo Clin Proc* 2009 Jul;84(7):602-612.

27. Ballantyne JC. Opioids around the clock? *Pain* 2011 Jun;152(6):1221-1222.
28. Canadian Agency for Drugs and Technologies in Health. Watchful Dosing of Morphine or Morphine Equivalent Dosing in the Treatment of Chronic Non-Cancer Pain: A Review of the Clinical Evidence. 2012; Available at: <http://www.cadth.ca/media/pdf/htis/june-2012/RC0353%20Watchful%20Dose%20Final.pdf>. Accessed June 17, 2013.
29. British Pain Society. Opioids for persistent pain: good practice. 2010; Available at: http://www.britishpainsociety.org/book_opioid_main.pdf. Accessed June 17, 2013.
30. Gomes T, Mamdani MM, Dhalla IA, Paterson JM, Juurlink DN. Opioid dose and drug-related mortality in patients with nonmalignant pain. *Arch Intern Med* 2011 Apr 11;171(7):686-691.
31. Gomes T, Juurlink DN, Dhalla IA, Mailis-Gagnon A, Paterson JM, Mamdani MM. Trends in opioid use and dosing among socio-economically disadvantaged patients. *Open Med* 2011;5(1):e13-22.
32. Bohnert AS, Valenstein M, Bair MJ, Ganoczy D, McCarthy JF, Ilgen MA, et al. Association between opioid prescribing patterns and opioid overdose-related deaths. *JAMA* 2011 Apr 6;305(13):1315-1321.
33. Dunn KM, Saunders KW, Rutter CM, Banta-Green CJ, Merrill JO, Sullivan MD, et al. Opioid prescriptions for chronic pain and overdose: a cohort study. *Ann Intern Med* 2010 Jan 19;152(2):85-92.
34. Paulozzi LJ, Kilbourne EM, Shah NG, Nolte KB, Desai HA, Landen MG, et al. A history of being prescribed controlled substances and risk of drug overdose death. *Pain Med* 2012 Jan;13(1):87-95.
35. BC Coroners Service. Opiate Deaths. 2013; Available at: <http://www.pssg.gov.bc.ca/coroners/publications/docs/OpiateDeaths.pdf>. Accessed June 17, 2013.
36. Food and Drug Administration (FDA). Extended-release (ER) and long-acting (LA) opioid analgesics risk evaluation and mitigation strategy (REMS). 2013; Available at: <http://www.fda.gov/downloads/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/UCM311290.pdf>. Accessed June 17, 2013.
37. Dhalla IA, Mamdani MM, Sivilotti ML, Kopp A, Qureshi O, Juurlink DN. Prescribing of opioid analgesics and related mortality before and after the introduction of long-acting oxycodone. *CMAJ* 2009 Dec 8;181(12):891-896.
38. Manchikanti L, Abdi S, Atluri S, Balog CC, Benyamin RM, Boswell MV, et al. American Society of Interventional Pain Physicians (ASIPP) guidelines for responsible opioid prescribing in chronic non-cancer pain: Part I—evidence assessment. *Pain Physician* 2012 Jul;15(3 Suppl):S1-65.
39. Kahan M, Mailis-Gagnon A, Wilson L, Srivastava A, National Opioid Use Guideline Group. Canadian guideline for safe and effective use of opioids for chronic noncancer pain: clinical summary for family physicians. Part 1: general population. *Can Fam Physician* 2011 Nov;57(11):1257-1266.
40. Canadian Pharmacists Association. e-CPS. 2013; Available at: <http://www.e-therapeutics.ca>. Accessed May 13, 2013.
41. Trescot AM, Datta S, Lee M, Hansen H. Opioid pharmacology. *Pain Physician* 2008 Mar;11(2 Suppl):S133-153.
42. Smith HS. Opioid metabolism. *Mayo Clin Proc* 2009 Jul;84(7):613-624.
43. King S, Forbes K, Hanks GW, Ferro CJ, Chambers EJ. A systematic review of the use of opioid medication for those with moderate to severe cancer pain and renal impairment: a European Palliative Care Research Collaborative opioid guidelines project. *Palliat Med* 2011 Jul;25(5):525-552.
44. Gillman PK. Monoamine oxidase inhibitors, opioid analgesics and serotonin toxicity. *Br J Anaesth* 2005 Oct;95(4):434-441.
45. Gillman PK. CNS toxicity involving methylene blue: the exemplar for understanding and predicting drug interactions that precipitate serotonin toxicity. *J Psychopharmacol* 2010 Mar;25(3):429-436.

46. BC Renal Agency. Renal analgesic brochure. 2011; Available at: <http://www.bcrenalagency.ca/sites/default/files/documents/files/Renal-Analgesic-Brochure.pdf>. Accessed June 17, 2013.
47. Overholser BR, Foster DR. Opioid pharmacokinetic drug-drug interactions. *Am J Manag Care* 2011 Sep;17 Suppl 11:S276-287.
48. Vallejo R, Barkin RL, Wang VC. Pharmacology of opioids in the treatment of chronic pain syndromes. *Pain Physician* 2011;14(4):E343-360.
49. Crews KR, Gaedigk A, Dunnenberger HM, Klein TE, Shen DD, Callaghan JT, et al. Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines for codeine therapy in the context of cytochrome P450 2D6 (CYP2D6) genotype. *Clin Pharmacol Ther* 2012 Feb;91(2):321-326.
50. Health Canada. Use of codeine products by nursing mothers. 2008; Available at: <http://www.healthycanadians.gc.ca/recall-alert-rappel-avis/hc-sc/2008/13255a-eng.php>. Accessed June 17, 2013.
51. Canadian Agency for Drugs and Technologies in Health. CEDAC final recommendation and reasons for recommendation: hydromorphone hydrochloride (Jurnista – Janssen-Ortho Inc.). 2010; Available at: http://www.cadth.ca/media/cdr/complete/cdr_complete_Jurnista_May-19-2010.pdf. Accessed June 17, 2013.
52. Health Canada. Notice of Decision for ^NOxyNeoTM. 2011; Available at: http://www.hc-sc.gc.ca/dhp-mps/prodpharma/sbd-smd/drug-med/nd_ad_2012_oxyleneo_141379-eng.php. Accessed June 17, 2013.
53. Health Canada. Letter to provincial and territorial Health Ministers regarding generic OxyContin. 2012; Available at: http://www.hc-sc.gc.ca/ahc-asc/media/fttr-ati/2012/2012_173-eng.php. Accessed June 17, 2013.
54. Canadian Agency for Drugs and Technologies in Health. CEDAC final recommendation on reconsideration and reasons for recommendation: oxycodone hydrochloride/naloxone hydrochloride (Targin – Purdue Pharma). 2012; Available at: http://www.cadth.ca/media/cdr/complete/cdr_complete_Targin_2_Jan-27-12_e.pdf. Accessed June 17, 2013.
55. Raymond B, Morawiecka I. Transdermal fentanyl (Duragesic): respiratory arrest in adolescents. *Can Advers React Newsl* 2004;14(4):1-2.
56. Raymond B. Transdermal fentanyl (Duragesic): abuse in adolescents. *Can Adverse React Newsl* 2005;15(3):1.
57. McMorran M, Longo M. Fentanyl transdermal patch and fatal adverse reactions. *Can Adverse React Newsl* 2008;18(3):1-2.
58. Ferrand S. Fentanyl and serotonin syndrome. *Can Adverse React Newsl* 2012;22(2):2-3.
59. Food and Drug Administration (FDA). FDA reminds the public about the potential for life-threatening harm from accidental exposure to fentanyl transdermal systems (“patches”). 2012; Available at: <http://www.fda.gov/Drugs/DrugSafety/ucm300747.htm>. Accessed June 17, 2013.
60. Boyer EW, Shannon M. The serotonin syndrome. *N Engl J Med* 2005 Mar 17;352(11):1112-1120.
61. Purdue Pharma LP. BuTransTM (buprenorphine) transdermal system: risk evaluation and mitigation strategy (REMS). 2010; Available at: <http://www.fda.gov/downloads/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/UCM220880.pdf>. Accessed June 17, 2013.
62. Grond S, Sablotzki A. Clinical pharmacology of tramadol. *Clin Pharmacokinet* 2004;43(13):879-923.
63. Pharmacist's Letter/Prescriber's Letter. PL Detail-Document #270371. Comparison of tramadol products. 2012 July 2012.

- 
64. Gevirtz C. A comparative analysis of tapentadol, tramadol, and the opiates. *Top Pain Manage* 2010;25(8):1-7.
 65. Vadivelu N, Timchenko A, Huang Y, Sinatra R. Tapentadol extended-release for treatment of chronic pain: a review. *J Pain Res* 2011;4:211-218.
 66. Health Canada. Summary basis of decision (SBD): ^NNucynta™ CR: tapentadol hydrochloride controlled-release tablets. 2011; Available at: http://www.hc-sc.gc.ca/dhp-mps/alt_formats/pdf/prodpharma/sbd-smd/phase1-decision/drug-med/sbd_smd_2011_nucynta_cr_133167-eng.pdf. Accessed June 17, 2013.
 67. Merriam-Webster. Merriam-Webster Online Dictionary. 2013; Available at: <http://www.merriam-webster.com/dictionary/stewardship>. Accessed June 17, 2013.
 68. Institute for Safe Medication Practices (ISMP). ISMP's list of error-prone abbreviations, symbols, and dose designations. 2013; Available at: <http://www.ismp.org/tools/errorproneabbreviations.pdf>. Accessed June 17, 2013.
 69. Institute for Safe Medication Practices (ISMP) Canada. Do not use: dangerous abbreviations, symbols and dose designations. 2013; Available at: <http://www.ismp-canada.org/download/ISMPCanadaListOfDangerousAbbreviations.pdf>. Accessed June 17, 2013.